• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: introduction.来自国家癌症研究所第二次关于造血干细胞移植后复发的生物学、预防和治疗的国际研讨会的会议记录:引言。
Biol Blood Marrow Transplant. 2013 Nov;19(11):1534-6. doi: 10.1016/j.bbmt.2013.08.016. Epub 2013 Sep 10.
2
National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee.美国国立癌症研究所首届异基因造血干细胞移植后复发的生物学、预防和治疗国际研讨会:组织委员会总结和建议。
Biol Blood Marrow Transplant. 2011 Apr;17(4):443-54. doi: 10.1016/j.bbmt.2010.12.713. Epub 2011 Jan 9.
3
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation.从美国国家癌症研究所第二次造血干细胞移植后复发的生物学、预防和治疗国际研讨会的会议记录:第一部分。移植后复发的生物学。
Biol Blood Marrow Transplant. 2013 Nov;19(11):1537-45. doi: 10.1016/j.bbmt.2013.08.010. Epub 2013 Sep 6.
4
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies.美国国立癌症研究所造血干细胞移植后复发的生物学、预防及治疗第二次国际研讨会论文集:第二部分。自体移植——新型药物与免疫调节策略
Biol Blood Marrow Transplant. 2013 Dec;19(12):1661-9. doi: 10.1016/j.bbmt.2013.08.011. Epub 2013 Sep 7.
5
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation.来自国家癌症研究所第二次造血干细胞移植后复发的生物学、预防和治疗国际研讨会的会议记录:第三部分。异基因移植后复发的预防和治疗。
Biol Blood Marrow Transplant. 2014 Jan;20(1):4-13. doi: 10.1016/j.bbmt.2013.08.012. Epub 2013 Sep 7.
6
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation.NCI 首届同种异体造血干细胞移植后复发的生物学、预防和治疗国际研讨会:来自异体细胞移植后复发的流行病学和自然史委员会的报告。
Biol Blood Marrow Transplant. 2010 Jul;16(7):871-90. doi: 10.1016/j.bbmt.2010.04.004. Epub 2010 Apr 24.
7
Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.美国国立癌症研究所关于异基因造血干细胞移植后复发的生物学、预防及治疗的首次国际研讨会报告介绍
Biol Blood Marrow Transplant. 2010 May;16(5):563-4. doi: 10.1016/j.bbmt.2010.02.025. Epub 2010 Mar 2.
8
NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction.NCI 首次同种异体造血干细胞移植后复发的生物学、预防和治疗国际研讨会:来自同种异体 HSCT 后恶性疾病复发的生物学基础研究委员会的报告:移植物抗白血病/肿瘤反应。
Biol Blood Marrow Transplant. 2010 May;16(5):565-86. doi: 10.1016/j.bbmt.2010.02.005. Epub 2010 Feb 10.
9
NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies.NCI 首次国际造血细胞移植后复发的生物学、预防和治疗专题研讨会:血液恶性肿瘤异基因细胞移植后预防复发专题委员会报告。
Biol Blood Marrow Transplant. 2010 Aug;16(8):1037-69. doi: 10.1016/j.bbmt.2010.05.005. Epub 2010 May 24.
10
NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science.NCI 首届异基因造血干细胞移植后复发的生物学、预防和治疗国际研讨会:来自非移植物抗宿主病相关造血系统复发的生物学考虑因素委员会的报告:科学现状。
Biol Blood Marrow Transplant. 2010 Jun;16(6):709-28. doi: 10.1016/j.bbmt.2010.03.002. Epub 2010 Mar 12.

引用本文的文献

1
IFN-γ and donor leukocyte infusions for relapsed myeloblastic malignancies after allogeneic hematopoietic stem cell transplantation.干扰素-γ与供体白细胞输注用于异基因造血干细胞移植后复发的髓母细胞性恶性肿瘤
JCI Insight. 2025 Mar 25;10(9). doi: 10.1172/jci.insight.190655. eCollection 2025 May 8.
2
Development of TCR-T cell therapy targeting mismatched HLA-DPB1 for relapsed leukemia after allogeneic transplantation.针对异基因移植后复发白血病的错配 HLA-DPB1 靶向 TCR-T 细胞治疗的开发。
Int J Hematol. 2023 Aug;118(2):252-266. doi: 10.1007/s12185-023-03621-y. Epub 2023 Jun 13.
3
The Hippo signaling pathway in leukemia: function, interaction, and carcinogenesis.白血病中的河马信号通路:功能、相互作用及致癌作用
Cancer Cell Int. 2021 Dec 25;21(1):705. doi: 10.1186/s12935-021-02408-7.
4
Case Report: Combination Therapy With PD-1 Blockade for Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation Resulted in Fatal GVHD.病例报告:异基因造血干细胞移植后接受 PD-1 阻断联合治疗导致致命移植物抗宿主病的急性髓系白血病。
Front Immunol. 2021 Apr 1;12:639217. doi: 10.3389/fimmu.2021.639217. eCollection 2021.
5
T cell exhaustion and a failure in antigen presentation drive resistance to the graft-versus-leukemia effect.T细胞耗竭和抗原呈递功能障碍导致对移植物抗白血病效应产生抗性。
Nat Commun. 2020 Aug 24;11(1):4227. doi: 10.1038/s41467-020-17991-y.
6
Checkpoint inhibitors in AML: are we there yet?AML 中的检查点抑制剂:我们成功了吗?
Br J Haematol. 2020 Jan;188(1):159-167. doi: 10.1111/bjh.16358. Epub 2019 Dec 6.
7
Cells to prevent/treat relapse following allogeneic stem cell transplantation.预防/治疗异基因干细胞移植后复发的细胞。
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):708-715. doi: 10.1182/asheducation-2017.1.708.
8
Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.抗CD22免疫毒素莫克妥昔单抗帕苏妥昔用于儿童急性淋巴细胞白血病的1期研究。
Blood. 2017 Oct 5;130(14):1620-1627. doi: 10.1182/blood-2017-02-749101. Epub 2017 Aug 9.
9
KIR3DL1/HLA-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation.KIR3DL1/HLA - B亚型决定造血细胞移植后急性髓系白血病的复发情况。
J Clin Oncol. 2017 Jul 10;35(20):2268-2278. doi: 10.1200/JCO.2016.70.7059. Epub 2017 May 18.
10
Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes.脐带血移植治疗骨髓增生异常综合征后的疗效
Biol Blood Marrow Transplant. 2017 Jun;23(6):971-979. doi: 10.1016/j.bbmt.2017.03.014. Epub 2017 Mar 10.

本文引用的文献

1
Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.阿扎胞苷和供者淋巴细胞输注作为异基因造血干细胞移植后 AML 或 MDS 复发的一线挽救治疗。
Leukemia. 2013 Jun;27(6):1229-35. doi: 10.1038/leu.2013.7. Epub 2013 Jan 14.
2
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.来那度胺维持治疗多发性骨髓瘤患者干细胞移植后。
N Engl J Med. 2012 May 10;366(19):1782-91. doi: 10.1056/NEJMoa1114138.
3
Lenalidomide after stem-cell transplantation for multiple myeloma.来那度胺用于多发性骨髓瘤患者干细胞移植后。
N Engl J Med. 2012 May 10;366(19):1770-81. doi: 10.1056/NEJMoa1114083.
4
Clonal architecture of secondary acute myeloid leukemia.继发性急性髓系白血病的克隆结构。
N Engl J Med. 2012 Mar 22;366(12):1090-8. doi: 10.1056/NEJMoa1106968. Epub 2012 Mar 14.
5
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing.全基因组测序揭示复发急性髓系白血病的克隆进化。
Nature. 2012 Jan 11;481(7382):506-10. doi: 10.1038/nature10738.
6
National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee.美国国立癌症研究所首届异基因造血干细胞移植后复发的生物学、预防和治疗国际研讨会:组织委员会总结和建议。
Biol Blood Marrow Transplant. 2011 Apr;17(4):443-54. doi: 10.1016/j.bbmt.2010.12.713. Epub 2011 Jan 9.
7
Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia.三名移植后复发的急性淋巴细胞白血病儿科患者在使用博纳吐单抗诱导供体T细胞激活后实现完全缓解。
Leukemia. 2011 Jan;25(1):181-4. doi: 10.1038/leu.2010.239. Epub 2010 Oct 14.
8
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.NCI 首次异基因造血干细胞移植后复发的生物学、预防和治疗国际研讨会:来自异基因造血干细胞移植后复发治疗委员会的报告。
Biol Blood Marrow Transplant. 2010 Nov;16(11):1467-503. doi: 10.1016/j.bbmt.2010.08.001. Epub 2010 Aug 10.
9
Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.异基因造血干细胞移植后低剂量阿扎胞苷维持治疗复发性急性髓系白血病或骨髓增生异常综合征:剂量和方案发现研究。
Cancer. 2010 Dec 1;116(23):5420-31. doi: 10.1002/cncr.25500. Epub 2010 Jul 29.
10
NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies.NCI 首届异基因造血干细胞移植后复发的生物学、预防和治疗国际研讨会:来自异体干细胞移植后复发疾病特异性方法和策略委员会的报告。第二部分:慢性白血病、骨髓增生性肿瘤和淋巴恶性肿瘤。
Biol Blood Marrow Transplant. 2010 Oct;16(10):1325-46. doi: 10.1016/j.bbmt.2010.07.001. Epub 2010 Jul 15.

来自国家癌症研究所第二次关于造血干细胞移植后复发的生物学、预防和治疗的国际研讨会的会议记录:引言。

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: introduction.

机构信息

Children's Center for Cancer and Blood Diseases, Division of Hematology, Oncology, and Blood and Marrow Transplantation, Children's Hospital Los Angeles, The Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California; Organizing Committee, National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation.

出版信息

Biol Blood Marrow Transplant. 2013 Nov;19(11):1534-6. doi: 10.1016/j.bbmt.2013.08.016. Epub 2013 Sep 10.

DOI:10.1016/j.bbmt.2013.08.016
PMID:24035783
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3880421/
Abstract

Despite advances in hematopoietic stem cell transplantation (HSCT) for the treatment of hematologic malignancies, relapse remains the leading cause of death after transplant. Biologic and clinical investigations are needed to combat this primary cause of death after transplantation. The National Cancer Institute held international workshops in 2009 and 2012 to help address this problem. Three major initiatives for coordinated research were proposed: 1) To establish multicenter networks for basic, translational, epidemiologic and clinical research; 2) To establish a network of biorepositories for the collection of samples before and after HSCT to aid in laboratory and clinical studies; and 3) To refine, implement and study proposed definitions for disease-specific response and relapse and for monitoring of minimal residual disease. The workshop in 2012 also featured nine presentations, summaries of which follow in three manuscripts.

摘要

尽管造血干细胞移植(HSCT)在治疗血液系统恶性肿瘤方面取得了进展,但移植后复发仍是导致死亡的主要原因。需要进行生物学和临床研究来对抗移植后这一主要死亡原因。美国国家癌症研究所于 2009 年和 2012 年举办了国际研讨会,以帮助解决这一问题。提出了三项协调研究的主要倡议:1)建立用于基础、转化、流行病学和临床研究的多中心网络;2)建立生物库网络,在 HSCT 前后收集样本,以辅助实验室和临床研究;3)完善、实施和研究针对疾病特异性反应和复发以及最小残留疾病监测的建议定义。2012 年的研讨会还包括 9 个专题介绍,以下是其中 3 篇专题介绍的摘要。